$BMEA

Picard Medical (PMI) rose 40% after reporting Q2 revenue growth of 39% to $3.0M. Sadot Group (SDOT) surged 100% despite zero revenue, with net income up to $35.2M. Capricor Therapeutics (CAPR) gained 11% after FDA extended review for deramiocel. GRI Bio (GRI) climbed 10% with Phase 2a data selected for ERS 2026. Biomea Fusion (BMEA) rose 14% after completing Phase 2 diabetes trial enrollment. Yarrow Bioscience (YARW) advanced 12% with Graves' disease trial updates.

Biomea Fusion Inc (BMEA) shares rose 27% after completing enrollment in its Phase II diabetes trial COVALENT-211. The trial evaluates icovamenib in type 2 diabetes patients. Topline results are expected in Q1 2027. H.C. Wainwright analyst reiterated a Buy rating and $4.00 price target, citing potential for future Phase 3 trials.

Biomea Fusion (BMEA) stock rose 5.8% pre-market to $1.45 ahead of anticipated 28-day weight-reduction data from its Phase I GLP-131 trial, expected by Q3 2026. Recent positive developments include the first patient dosed in the OPAL study, analyst optimism, and better-than-expected Q2 earnings. The stock remains below its 52-week high of $2.99.

Biomea Fusion, Inc. (BMEA) is scheduled to report Q2 2026 earnings on Aug. 3 at 8:00 AM ET. The consensus outlook cited for the quarter calls for revenue of $0 and EPS of -$0.22 (USD).

Biomea Fusion, Inc. (BMEA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001840439 0001840439 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10,

Rodman & Renshaw has initiated coverage on Biomea Fusion Inc. (NASDAQ:BMEA) with a Buy rating and a price target of $8.00, suggesting over 500% potential upside. The firm believes Biomea's current valuation disconnects from its clinical progress, highlighting "early clinical validation of a genuine disease-modifying mechanism." This comes as Biomea plans Phase II trials for its diabetes drug, icovamenib, despite a recent downgrade from JPMorgan due to concerns regarding type 2 diabetes data.

SAN CARLOS, Calif., Oct. 21, 2025 ( GLOBE NEWSWIRE ) -- Biomea Fusion, Inc. ( "Biomea" ) ( NASDAQ:BMEA ) , a clinical-stage diabetes and obesity company, today announced that it will participate in Citi's SMID Biotech C-Suite Fireside Chat Series on Thursday, October 23, 2025, at 8:00 a.m.

SAN CARLOS, Calif., Oct. 21, 2025 ( GLOBE NEWSWIRE ) -- Biomea Fusion, Inc. ( "Biomea" ) ( Nasdaq: BMEA ) , a clinical-stage diabetes and obesity company, today announced that it will participate in Citi's SMID Biotech C-Suite Fireside Chat Series on Thursday, October 23, 2025, at 8:00 a.m.

Biomea Fusion Inc's ( NASDAQ:BMEA ) stock price plummeted after the company priced its public offering. The public offering includes 11.2 million shares of common stock and accompanying warrants to purchase an equal number of shares.

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 100 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.33% to 46,847.49 while the NASDAQ rose 0.11% to 22,967.90. The S&P 500 also rose, gaining, 0.15% to 6,750.64.